J&J’s Gorsky Stands By Remicade Longevity As Biosimilar Impact Hits Europe
This article was originally published in The Pink Sheet Daily
"We expect the biosimilar market to behave quite differently" than generics, CEO Alex Gorsky says even as international sales of Remicade fell 20% in the second quarter, though largely due to currency.
You may also be interested in...
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.